US4431833A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prostaglandin and hydroxylated fatty acid ester formulations
Assignee: Wyeth Holdings LLC
•
Filing: 1982-12-27
•
Granted: 1984-02-14
•
Expires: 2002-12-27
Abstract
Abstract Degradation of E-type prostaglandin compounds is retarded by dissolving or suspending such compounds in formulations containing hydroxylated derivatives of fatty acids having the formula: ##STR1## wherein R 1 is C 2 -C 24 alkyl, R 2 is C 2 -C 24 alkyl and n is an integer from 1-6, denoting from 1 to 6 hydroxyl groups which may be substituted in R 1 or R 2 .
Inventors
- 👤 Shahid A. Lodhi
- 👤 Bernard Sims
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 08:59
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/557; A61K47/00; A61K47/06; A61K47/08; A61K47/14; A61K9/00; A61K9/0012; A61K9/0014; A61P; A61P43/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
80 words
A method for stabilizing E-type prostaglandins comprising the step of admixing an E-type prostaglandin with an amount of hydroxylated derivative of a fatty acid having the formula ##STR8## where R 1 is C 2 -C 24 alkyl; R 2 is C 2 -C 24 alkyl; and n is an integer from 1 to 6, denoting from 1 to 6 hydroxyl groups which may be substituted in the alkyl groups R 1 or R 2 , effective to stabilize the prostaglandin.
Claim 2
Independent Claim
80 words
A method for stabilizing E-type prostaglandins comprising the step of admixing an E-type prostaglandin with an amount of hydroxylated derivative of a fatty acid having the formula ##STR8## where R 1 is C 2 -C 24 alkyl; R 2 is C 2 -C 24 alkyl; and n is an integer from 1 to 6, denoting from 1 to 6 hydroxyl groups which may be substituted in the alkyl groups R 1 or R 2 , effective to stabilize the prostaglandin.
Claim 3
Dependent Claim
12 words
The method as recited in claim 1, wherein the prostaglandin is 1-hydroxy-8-[3α-hydroxy-2β-(4-hydroxy-4-methyl-1-octenyl)-5-oxo-1α-cyclopentyl]-2-octanone.
Claim 4
Dependent Claim
15 words
The method as recited in claim 1, wherein the prostaglandin is 7-[2β-(4-butyl-4-hydroxy-1,5-hexadienyl)-3α-hydroxy-5-oxo-1.alpha.-cyclopentyl]-5-heptenoic acid, methyl ester.
Claim 5
Dependent Claim
17 words
The method as recited in claim 1, wherein the hydroxylated derivative of a fatty acid is 2-ethylhexyl-12-hydroxystearate.
Claim 6
Dependent Claim
33 words
The method as recited in claim 1, wherein about one milliliter of the hydroxylated derivative of a fatty acid is admixed with between about 0.0001 mg to about 200 mg of the prostaglandin.
Claim 7
Dependent Claim
75 words
A stable E-type prostaglandin formulation comprising an E-type prostaglandin, and an amount of hydroxylated derivative of a fatty acid represented by the formula ##STR9## wherein R 1 is C 2 -C 24 alkyl; R 2 is C 2 -C 24 alkyl; and wherein n is an integer from 1 to 6, denoting from 1 to 6 hydroxyl groups which may be substituted in alkyl groups R 1 or R 2 effective to stabilize the prostaglandin.
Claim 8
Dependent Claim
75 words
A stable E-type prostaglandin formulation comprising an E-type prostaglandin, and an amount of hydroxylated derivative of a fatty acid represented by the formula ##STR9## wherein R 1 is C 2 -C 24 alkyl; R 2 is C 2 -C 24 alkyl; and wherein n is an integer from 1 to 6, denoting from 1 to 6 hydroxyl groups which may be substituted in alkyl groups R 1 or R 2 effective to stabilize the prostaglandin.
Claim 9
Dependent Claim
12 words
The formulation as recited in claim 6 wherein the prostaglandin is 1-hydroxy-8-[3α-hydroxy-2β-(4-hydroxy-4-methyl-1-octenyl)-5-oxo-1α-cyclopentyl]-2-octanone.
Claim 10
Dependent Claim
15 words
The formulation as recited in claim 6 wherein the prostaglandin is 7-[2β-(4-butyl-4-hydroxy-1,5-hexadienyl)-3α-hydroxy-5-oxo-1.alpha.-cyclopentyl]-5-heptenoic acid, methyl ester.
Claim 11
Dependent Claim
17 words
The formulation as recited in claim 6 wherein the hydroxylated derivative of a fatty acid is 2-ethylhexyl-12-hydroxystearate.
Claim 12
Dependent Claim
32 words
The formulation as recited in claim 6 wherein the amount of hydroxylated derivative of a fatty acid is about one milliliter per about 0.0001 mg to about 200 mg of the prostaglandin.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-02-13 | 1987-08-15 | 1988-02-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-02-13 | 1991-08-15 | 1992-02-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-02-13 | 1995-08-15 | 1996-02-14 | $7700.00 | Window Closed / Lapsed |